key: cord-0838241-thko9six authors: Mosha, Jacklin F; Kulkarni, Manisha A; Lukole, Eliud; Matowo, Nancy S; Pitt, Catherine; Messenger, Louisa A; Mallya, Elizabeth; Jumanne, Mohamed; Aziz, Tatu; Kaaya, Robert; Shirima, Boniface A; Isaya, Gladness; Taljaard, Monica; Martin, Jacklin; Hashim, Ramadhan; Thickstun, Charles; Manjurano, Alphaxard; Kleinschmidt, Immo; Mosha, Franklin W; Rowland, Mark; Protopopoff, Natacha title: Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial date: 2022-03-26 journal: Lancet DOI: 10.1016/s0140-6736(21)02499-5 sha: c4c864ebf4be8ac95d224968ee4b6b8d726186e4 doc_id: 838241 cord_uid: thko9six BACKGROUND: Long-lasting insecticidal nets (LLINs) have successfully reduced malaria in sub-Saharan Africa, but their effectiveness is now partly compromised by widespread resistance to insecticides among vectors. We evaluated new classes of LLINs with two active ingredients with differing modes of action against resistant malaria vectors. METHODS: We did a four-arm, cluster-randomised trial in Misungwi, Tanzania. Clusters were villages, or groups of hamlets, with at least 119 households containing children aged 6 months to 14 years living in the cluster's core area. Constrained randomisation was used to allocate clusters (1:1:1:1) to receive one of four types of LLIN treated with the following: α-cypermethrin only (pyrethroid-only [reference] group); pyriproxyfen and α-cypermethrin (pyriproxyfen group); chlorfenapyr and α-cypermethrin (chlorfenapyr group); or the synergist piperonyl butoxide and permethrin (piperonyl butoxide group). At least one LLIN was distributed for every two people. Community members and the field team were masked to group allocation. Malaria prevalence data were collected through cross-sectional surveys of randomly selected households from each cluster, in which children aged 6 months to 14 years were assessed for Plasmodium falciparum malaria infection by rapid diagnostic tests. The primary outcome was malaria infection prevalence at 24 months after LLIN distribution, comparing each of the dual-active-ingredient LLINs to the standard pyrethroid-only LLINs in the intention-to-treat population. The primary economic outcome was cost-effectiveness of dual-active-ingredient LLINs, based on incremental cost per disability-adjusted life-year (DALY) averted compared with pyrethroid-only LLINs, modelled over a 2-year period; we included costs of net procurement and malaria diagnosis and treatment, and estimated DALYs in all age groups. This study is registered with ClinicalTrials.gov (NCT03554616), and is ongoing but no longer recruiting. FINDINGS: 84 clusters comprising 39 307 households were included in the study between May 11 and July 2, 2018. 147 230 LLINs were distributed among households between Jan 26 and Jan 28, 2019. Use of study LLINs was reported in 3155 (72·1%) of 4378 participants surveyed at 3 months post-distribution and decreased to 8694 (40·9%) of 21 246 at 24 months, with varying rates of decline between groups. Malaria infection prevalence at 24 months was 549 (45·8%) of 1199 children in the pyrethroid-only reference group, 472 (37·5%) of 1258 in the pyriproxyfen group (adjusted odds ratio 0·79 [95% CI 0·54–1·17], p=0·2354), 512 (40·7%) of 1259 in the piperonyl butoxide group (0·99 [0·67–1·45], p=0·9607), and 326 [25·6%] of 1272 in the chlorfenapyr group (0·45 [0·30–0·67], p=0·0001). Skin irritation or paraesthesia was the most commonly reported side-effect in all groups. Chlorfenapyr LLINs were the most cost-effective LLINs, costing only US$19 (95% uncertainty interval 1–105) more to public providers or $28 (11–120) more to donors per DALY averted over a 2-year period compared with pyrethroid-only LLINs, and saving costs from societal and household perspectives. INTERPRETATION: After 2 years, chlorfenapyr LLINs provided significantly better protection than pyrethroid-only LLINs against malaria in an area with pyrethroid-resistant mosquitoes, and the additional cost of these nets would be considerably below plausible cost-effectiveness thresholds ($292–393 per DALY averted). Before scale-up of chlorfenapyr LLINs, resistance management strategies are needed to preserve their effectiveness. Poor textile and active ingredient durability in the piperonyl butoxide and pyriproxyfen LLINs might have contributed to their relative lack of effectiveness compared with standard LLINs. FUNDING: Joint Global Health Trials scheme (UK Foreign, Commonwealth and Development Office; UK Medical Research Council; Wellcome; UK Department of Health and Social Care), US Agency for International Development, President's Malaria Initiative. Effectiveness and cost-effectiveness against malaria of three types of dualactive-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial The figure shows the proportion of different types of nets found in households. "Study net" includes all the nets distributed at the start of the trial by the project. The table shows the concentration of active ingredient (insecticide and PBO synergist) in the study nets when new and after 12 and 24 months of use in the community. *Polyester nets coated with the AI plus a binder to make them wash resistance ** AI and PBO incorporated into polyethylene fibres. Page 10 of 35 The figures show the reduction in pyrethroid and second AI content compared to initial content (t0) in each of the study nets after 12 months (t12) and after 24 months (t24 The table presents secondary analyses of malaria prevalence alongside the primary analysis of odds ratios, which is presented in the main paper. To estimate the relative risk (RR), which reflects the relative reduction in malaria prevalence between the standard LLIN arm and each dual AI LLIN intervention arm at each survey timepoint, we used a mixed effects GLM with a log link, Poisson family and robust standard errors; similar results were observed as for other measures of effect, with a RR=0.63(95CI: 0.49 to 0.82, p=0.0005) observed in the CFP-Py LLIN arm at 24 months post-intervention. This figure shows the model structure for the full (all ages) population. The lower half of the figure shows children aged 6 months to 10 years (in turquoise). The upper half of the figure shows persons aged above 10 years (in purple). Straight turquoise and purple arrows indicate the flow of the population through the model. Curved blue arrows indicate where the population, number of malaria cases, and deaths in people aged over 10 years are estimated as a function of the corresponding number of children aged 6 months to 10 years, number of malaria cases in children, and number of deaths in children (see S20 and S21 for more information Trial estimates based on child cohort -See Table 3 in main paper; Standard deviations are calculated based on the natural logarithm (LN) of the bounds of the 95% confidence intervals calculated from the mean and sample size for the estimate in Table 3 . In the trial, malaria incidence was only measured in children aged 6 months to 10 years (CU10); however, LLINs may reduce malaria incidence and associated mortality in people of all ages. To capture the full health benefits of more effective LLINs, incidence and deaths in persons >10 years were modelled. In doing so, we sought to account for the epidemiology of malariaspecifically, that at higher population-level malaria incidence rates, more of the overall incidence is concentrated amongst younger age groups. We therefore analysed modelled estimates from the Global Burden of Disease (GBD) study to understand the relationship between malaria incidence in CU10 (as estimated in the trial) and the proportion of all malaria cases that are in CU10. Similarly, we used the GBD to estimate the relationship between malaria death rates in CU10 (as modelled from the trial data) and the proportion of all malaria deaths that are in CU10. We created two datasets in which each data point reflected estimates for a single country-year. All countries in the GBD were included with data points for each of the most recent 10 years available . These data are presented in blue in Figure S21 , with the ten data points for Tanzania presented in red. According to GBD estimates, in Tanzania in 2010, 55% of all malaria cases were in children under 10, and there were 243 cases per 1,000 children under 10. By 2019, the proportion of cases had fallen to 50%, while incidence fell to 198 cases per 1,000. These incidence rates lay between, but fairly distant from the upper and lower incidence bounds observed in the trial of 130 cases per 1,000 (in the chlorfenapyr LLIN arm in Y1) and 570 cases per 1,000 (in the standard arm in Y2). A log-linear regression was therefore conducted on all countryyears of data ( Figure S21 ), which produced a flatter, less extreme relationship than the Tanzania data points alone, and avoided extrapolation far beyond the range of the Tanzania data points while remaining broadly consistent with them. The estimates of the proportion of all cases expected to occur in children under 10 at the incidence rates observed in the four trial arms and 2 trial years are presented in Table S19 . Also according to GBD estimates, in Tanzania in 2010, 87% of all malaria deaths were in children under 10, and there were 122 malaria deaths per 100,000 children under 10. This malaria death rate was close to, but slightly lower than, the lowest death rate modelled for children under 10 in the trial (129 malaria deaths per 100,000 children under 10 with chlorfenapyr in Y1), and far lower than the highest mean death rate modelled (427 deaths per 100,000 children under 10 with standard LLINs in Y2). After 2010, GBD estimates indicated that Tanzania's malaria death rate fell rapidlyto 80 cases per 100,000 in 2012but the proportion of deaths that were in children remained as high as 86%. Compared with other countries, these proportions were near the top of the range; only Ethiopia had a higher proportion, with 93% of deaths in 2010 occurring in children under 10, falling to 89% of deaths in 2019. Given that the data for all countries were suggestive of a plateau, for the costeffectiveness analysis, we modelled the proportion of deaths that were in children as a fixed proportion, with mean of 86%, regardless of the malaria mortality rate. The figures present estimates from the Global Burden of Disease (GBD) for the years 2010-19, with our analysis and values used in the cost-effectiveness analysis superimposed. Each blue point represents a single country-year of GBD data for a country with non-zero malaria incidence (upper figure) or non-zero deaths (lower figure). Each red point represents a country-year of GBD data specific to Tanzania. Orange vertical lines represent the lowest and highest of the mean values for the four strategies compared in the trial in each of the two years for the incidence (upper figure) and death rate (lower figure) . Dotted turquoise lines show the equation used to calculate the proportion of all cases and deaths that would be expected to have occurred in children aged 6 months to 10 years as a function of the incidence rate or death rate in that age group. Malaria DALYs under each strategy were estimated as the sum of years of life lived with disability (YLDs) and years of life lost due to premature mortality (YLLs) with no age weighting and a 3% annual discount rate (in the base case). YLDs for all malaria cases were calculated separately for uncomplicated (requiring outpatient treatment only) and severe cases (defined as requiring hospitalisation) as the product of the population size, the incidence each year with standard nets, the rate ratio for that year, the probability of a case becoming severe, the duration of a case, and the disability weight for infectious disease (moderate or severe). (11) YLLs were estimated using WHO life tables for Tanzania. (17) Discounting was applied to remaining life expectancy for each 5-year age cohort. Mean discounted remaining life expectancy was then calculated for each of the two age cohorts in the model (CU10 vs. persons > 10y), weighted by the number of malaria deaths expected in each 5-year age cohort according to GBD estimates for Tanzania. Mean YLLs per death for each of the two age cohorts were then combined with modelled estimates of the number of deaths in each age cohort to estimate total YLLs for each strategy. Page 30 of 35 The following four panels disaggregate health effects and costs based on the deterministic cost-effectiveness analysis of the simulated cohort of 10,000 people. All values are shown without discounting. The cases, deaths, and DALYs figures illustrate the share of the total accounted for by children aged 6m to 10y, for which estimates are based directly on malaria case incidence measured in the trial. Cases, deaths, and DALYs in persons older than 10 years are estimated as a function of incidence and deaths in children under 10 using outputs from Global Burden of Disease model outputs (see Text S2, Figure S6 ). Costs are presented in constant 2020 United States dollars. CU10: Children aged 6m to 10y; DALYs: Disability-adjusted life-years; Dx: Diagnosis; LLINs: Long-lasting insecticide-treated bed nets (purchase price only); Tx: Treatment; YLD: Years of life lived with disability; YLL: Years of life lost to premature mortality. The tables below present the mean costs and effects of each of the four nets (S24a), and the incremental costs and effects (S24b) and cost-effectiveness (S24c) of the three dual active ingredient nets compared to standard nets over the 2-year period of the trial. Results presented reflect means of probabilistic uncertainty analysis and correspond with mean values presented on cost-effectiveness planes (Figure 3 in main paper) for the modelled cohort of 10,000 people (all ages). The combined costs of net procurement and diagnosis and treatment of malaria cases are presented for the societal, public provider, and donor perspectives; costs of net distribution are not included as they would be identical across strategies. The public provider perspective includes both costs to donors and costs to the domestically-funded public health service. The societal perspective includes both costs to public providers and also to households. For each dual active ingredient net, if it is both more costly and more effective than standard nets, the incremental cost per DALY averted compared with standard nets is shown. If the dual active ingredient net is less costly and more effective, it is described as "dominant"; if the dual AI net is more costly and less effective, it is described as "dominated"; in the case of dominant or dominated strategies, no incremental cost-effectiveness ratio (ICER) is shown because the ICER would be negative and difficult to interpret. To explore the influence of uncertainty and heterogeneity in individual parameters on cost-effectiveness results, the probabilistic uncertainty analyses presented in the main paper ( Figure 2 ) were re-run, with the value of one key parameter at a time held constant at a value different from the base case (Table S19 ). In this way, the analyses remain probabilistic, and continue to show the combined uncertainty in results, while also showing how overall results would vary if one key parameter were held constant at a value higher or lower than its mean in the base case. While various methods have been proposed to combine deterministic and probabilistic sensitivity analyses in similar ways, they are difficult to adapt to multi-way comparisons such as this one, which is why this particular approach was taken. These sensitivity analyses are all presented from the (public) provider perspective. The bowtie shape of the distribution of results on the cost-effectiveness plane for pyriproxyfen and PBO nets occurs because the rate ratios for the effectiveness of each of these nets with respect to standard nets includes 1 and the cost of the nets themselves has been modelled as a deterministic parameter. For a given iteration, if the random draw for the rate ratio is 1, there are no incremental effects relative to standard nets (and so the point is on y-axis), and the incremental costs relative to standard nets only consist of the additional cost of the nets themselves (a fixed parameter). S25a shows the impact of plausible variation in all key individual parameters except for the price of nets. S25b shows the variation in the price of each of the dual AI nets that would be necessary to change the recommendation about whether switching from standard nets to that specific dual AI net would be cost-effective at the more conservative cost-effectiveness threshold. CE: Cost-effectiveness; USD: United States dollars. This figure shows a threshold analysis, which identifies the price of each of the dual AI nets at which the incremental cost-effectiveness ratio would equal the more conservative (lower) cost-effectiveness threshold with respect to standard nets, and therefore the point at which the determination of cost-effectiveness would change. Assuming the cost of standard pyrethroid-only nets remains constant, PBO and chlorfenapyr LLINs would remain cost-effective relative to the more conservative cost-effectiveness threshold if their prices increased up to $3.72 and $10.13 per net, respectively, and Pyriproxyfen LLINs would become cost-effective if their price fell to $1.68 per net (appendix, p. 30). If the cost of standard pyrethroid-only nets were to change, the threshold prices shown here would change by the same absolute value; for example, if the cost of standard nets were to increase to $3.07, then chlorfenapyr LLINs would remain cost-effective up to a price of $11.13 in this context, assuming all else remained equal. Decision Modelling for Health Economic Evaluation Population Division of the Department of Economic and Social Affairs Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Population Estimates 1950-2019 Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME) The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data Global Burden of Disease Study 2019 (GBD 2019) Results Tool (GHDx) Seattle, United States of America: Institute for Health Metrics and Evaluation (IHME); 2020 [updated 29 World Health Organization 10. WHO. Global Health Observatory data repository: Life tables by country Geneva: World Health Organization Disability weights for the Global Burden of Disease 2013 study Pooled Procurement Mechanism Reference Pricing: LLINs Geneva: Global Fund Office of Chief Government Statistician -OCGS/Zanzibar, ICF. Tanzania Demographic and Health Survey and Malaria Indicator Survey Pooled Procurement Mechanism Reference Pricing: Malaria Rapid Diagnostic Tests (MRDT) Geneva: Global Fund WHO-CHOICE unit cost estimates for service delivery World Health Organization WHO. Global Health Observatory data repository: Life tables by country Geneva: World Health Organization